摘要
甲状腺未分化癌是最罕见但极具侵袭性的甲状腺癌亚型。 这种肿瘤是由未分化的肿瘤细胞组成,预后较差,并且对普通的甲状腺癌治疗具有抗性。 及早治疗癌症的早期鉴定非常重要。 目前,细针抽吸活检(FNAB)细胞学评估被称为侵袭性识别试验,是诊断恶性甲状腺肿瘤的标准诊断方法。 经常的研究表明,使用甲状腺癌组织分子生物标志物和细胞学检查,提高诊断试验的准确性。 此外,这些药物可能有利于有效的靶向治疗和个性化药物。 本文综述了甲状腺未分化癌分子生物标志物的基因突变特征,表观遗传学特征,microRNA特征和肿瘤干细胞标志物四大类。
关键词: 甲状腺未分化癌,分子生物标志物,基因突变谱,表观遗传谱,microRNA谱,癌症干细胞标志物。
Current Molecular Medicine
Title:Molecular Biomarkers of Anaplastic Thyroid Carcinoma
Volume: 17 Issue: 3
关键词: 甲状腺未分化癌,分子生物标志物,基因突变谱,表观遗传谱,microRNA谱,癌症干细胞标志物。
摘要: Anaplastic thyroid carcinoma is the rarest but extremely aggressive thyroid cancer subtype. This neoplasia is composed of undifferentiated tumor cells with poor prognosis and resistant to common thyroid cancer therapy. Early stage identification of this cancer for prompt treatment is very vital. Presently, cytological evaluation of fine needle aspiration biopsy (FNAB) which is known as invasive recognition assay, is the standard diagnostic method for the diagnosis of malignant thyroid tumors. Frequent studies have suggested that using the molecular biomarkers of thyroid cancer tissue alongside cytological examination, increase the accuracy of diagnostic tests. Also, these agents could be beneficial for effective target therapy and personalize medicine. In this review, the molecular biomarkers that are involved in anaplastic thyroid carcinoma in four category (gene mutation profile, epigenetic profile, microRNA profile and cancer stem cell markers) were summarized.
Export Options
About this article
Cite this article as:
Molecular Biomarkers of Anaplastic Thyroid Carcinoma, Current Molecular Medicine 2017; 17 (3) . https://dx.doi.org/10.2174/1566524017666170822102417
DOI https://dx.doi.org/10.2174/1566524017666170822102417 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Beyond Physical Exercise: The Role of Nutrition, Gut Microbiota and Nutraceutical Supplementation in Reducing Age-Related Sarcopenia
Current Aging Science Differentiated Thyroid Carcinoma and Intestinal Polyposis Syndromes
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Chemopreventive and Anti-leukemic Effects of Ethanol Extracts of Moringa oleifera Leaves on Wistar Rats Bearing Benzene Induced Leukemia
Current Pharmaceutical Biotechnology Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets RNA Splicing: Basic Aspects Underlie Antitumor Targeting
Recent Patents on Anti-Cancer Drug Discovery An Overview on 2-arylquinolin-4(1H)-ones and Related Structures as Tubulin Polymerisation Inhibitors
Current Topics in Medicinal Chemistry GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients
Current Hypertension Reviews The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry Anti-cancer Research on Arnebiae radix-derived Naphthoquinone in Recent Five Years
Recent Patents on Anti-Cancer Drug Discovery Circulating Tumor Cells: A New Window for Diagnosis and Evaluation of Cancer
Anti-Cancer Agents in Medicinal Chemistry Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Interaction of Drug or Food with Drug Transporters in Intestine and Liver
Current Drug Metabolism Targetability of Human Disease Genes
Current Drug Discovery Technologies Recent Advances in the Development of MMPIs and APNIs Based on the Pyrrolidine Platforms
Mini-Reviews in Medicinal Chemistry Development of Focal Adhesion Kinase Inhibitors in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Exploring the Possible Prognostic Role of B-Lymphocyte Stimulator (BLyS) in a Large Series of Patients with Neuroendocrine Tumors
Endocrine, Metabolic & Immune Disorders - Drug Targets Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design